Brief: Edgewise Therapeutics Announces Positive Two-Year Topline Results From The Arch Open Label Trial Of Sevasemten (Edg-5506) In Adults With Becker Muscular Dystrophy (Becker)
15/04/2024 22:12
April 15 (Reuters) - Edgewise Therapeutics Inc EWTX.O :
* EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TWO-YEAR TOPLINE
RESULTS FROM THE ARCH OPEN LABEL TRIAL OF SEVASEMTEN (EDG-5506)
IN ADULTS WITH BECKER MUSCULAR DYSTROPHY (BECKER)
* EDGEWISE THERAPEUTICS INC - SEVASEMTEN WAS WELL-TOLERATED
Source text for Eikon: ID:nBwbnwppXa
Further company coverage: EWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending